? Overall Component The overall objectives of the proposal are to improve the quality and quantity of cancer research and increase NIH funding at the University of Oklahoma Health Sciences Center (OUHSC), Oklahoma through the mentoring of promising junior Target investigators (Target investigators) and to develop support for the infrastructure for cancer research. Building on the success of the Phase I of this COBRE, the Phase II COBRE grant will support and sustain the infrastructure developed during the previous Phase I funding period in addition to mentoring a new cadre of target junior investigators. This COBRE will continue the process of strengthening cancer research in Oklahoma and enhance the research base, infrastructure, and core capacities of the Cancer Center. The focused and structured mentoring process of this COBRE will have a determinative influence helping TJIs achieve independent national funding. Finally, as has been observed with the Phase I of this COBRE, the Phase II grant will accelerate the development of the Cancer Center as it progresses towards submitting a competitive NCI Cancer Center Support Grant application. The overarching objective of the COBRE in enhancing the cancer research capacity of Oklahoma will be accomplished through the following specific aims: 1) To sustain the successful mentoring of promising junior target junior investigators in cancer research, enabling them to become independent NIH-funded investigators; 2) To support and strengthen the research infrastructure established during the Phase I of this COBRE; and 3) To foster and enhance multidisciplinary collaborative research to facilitate translational research.

Public Health Relevance

Overall Significance to Public Health (Project Narrative) Oklahoma has the 5th highest rate of cancer deaths per 100,000 among all states. The heavy burden of cancer in Oklahoma highlights the profound need for advanced cancer research that can lead to better therapeutic procedures. Building on the success of the COBRE Phase 1, the goal of this project is to continue the process of mentoring targeted junior investigators, with appropriate research infrastructure, to carry out high impact cancer research addressing the causes of and therapeutic approaches to reduce cancer burden.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM103639-07
Application #
9767770
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Davani, Behrous
Project Start
2012-09-05
Project End
2023-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
7
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Liu, Xuan; Shen, Tao; Mooers, Blaine H M et al. (2018) Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol 175:3504-3515
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Hays, Franklin A (2018) Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1). Molecules 23:
Jaiprasart, Pharavee; Yeung, Bertrand Z; Lu, Ze et al. (2018) Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release 270:101-113
Buechel, Megan; Dey, Anindya; Dwivedi, Shailendra Kumar Dhar et al. (2018) Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther 17:2136-2143
Ha, Ji Hee; Radhakrishnan, Rangasudhagar; Jayaraman, Muralidharan et al. (2018) LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res 78:1923-1934
Dey, Anindya; Xiong, Xunhao; Crim, Aleia et al. (2018) Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther 17:39-49
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Roe-Žurž, Zygy et al. (2018) Expression and purification of human and Saccharomyces cerevisiae equilibrative nucleoside transporters. Protein Expr Purif 142:68-74
Jiao, Yang; Watts, Tanya; Xue, Jing et al. (2018) Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1. BMC Cancer 18:1042
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Amreddy, Narsireddy; Babu, Anish; Panneerselvam, Janani et al. (2018) Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine 14:373-384

Showing the most recent 10 out of 68 publications